 |
인쇄하기
취소
|
KFDA approves Hepsera for treatment of chronic hepatitis B
GSK Korea said on February 19 that Hepsera (adefovir dipivoxil), an oral nucleotide analogue for the treatment of chronic hepatitis B, was approved by the Korea Food and Drug Administration.
The discovery of adefovir's potent inhibitory action on viral reverse transcriptase lead to exploration of its potential as an anti-HIV therapeutic agent, according to the company.
In two pivotal tri...
The discovery of adefovir's potent inhibitory action on viral reverse transcriptase lead to exploration of its potential as an anti-HIV therapeutic agent, according to the company.
In two pivotal tri...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.